Catalyst overview
Research summary
This catalyst tracks a Phase 1b data readout for NXP900 in YES1-amplified Non-small cell lung cancer. The expected timing is based on the latest available company guidance and may change.
9/12/23- Presentation at AACR '23. 10/24/24- Presentation at AACR '24. 4/29/25- Poster presentations at AACR '25. 7/8/25- Topline DDI study results. 8/13/25- Ph1b trial initiated. Presentations at AACR-NCI-EORTC'25. 11/04/25:- Ph1b monotherapy underway; combo part initiation expected by Year-End 2025. Ph1a and DDI studies completed. 12/17/25:- Ph1b combo with osimertinib initiated in EGFRmut+ NSCLC. Multiple Ph1b data readouts expected in 2026. 02/11/26:- Ph1b mono and osimertinib combo enrolling; lorlatinib combo pending start. Multiple Ph1b data readouts expected 2026. 03/31/26:- AACR 2026 posters scheduled Apr 21-22, 2026 on NSCLC and cholangiocarcinoma models. 05/05/26:- Ph1b mono and combos enrolling at US sites; prelim Ph1b data readout expected Summer 2026. 08/04/26:- Ph1b data expected Summer 2026; osimertinib update by Year-End 2026. Lorlatinib starts Q3 2026.
Verification
Confirm timing and program details against the company announcement or filing.